{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:04:39Z","timestamp":1782939879748,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To study the histological structure and immunohistochemical (IHC) parameters of the plasmacytoma tumour substrate in patients with multiple myeloma (MM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study included 21 patients (10 men\/11 women) aged 23 to 73\u2009years old with newly diagnosed MM complicated by plasmacytoma. Bone plasmacytoma was diagnosed in 14 patients, and extramedullary plasmacytoma was diagnosed in 7 patients. Plasmacytoma tissue specimens were examined using a LEICA DM4000B microscope. Anti-CD56, anti-CD166, anti-CXCR4, anti-Ki-67, and anti-c-MYC antibodies were used for IHC study of plasmacytoma biopsies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      When comparing the morphology of bone and extramedullary plasmacytoma, no significant differences were revealed; however, the substrate of extramedullary plasmacytoma was more often represented by tumour cells with an immature morphology than was the bone plasmacytoma substrate (57.1% vs. 28.6%, respectively). We revealed a significant difference in the expression of CD166 between bone and extramedullary plasmacytoma. The mean values \u200b\u200bof CD166 expression in bone plasmacytoma cells were significantly higher (36.29\u2009\u00b1\u20097.61% versus 9.57\u2009\u00b1\u20098.46%, respectively;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.033) than those in extramedullary plasmacytoma cells. We noticed that in extramedullary plasmacytoma cells, there were higher values for the Ki-67 index than in bone plasmacytoma cells, and this result was independent of cell morphology.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The mechanisms involved in the dissemination of tumour plasma cells are currently unexplored. Even in such a small sample, some differences in expression could be identified, which may indicate that different mechanisms lead to the formation of bone and extramedullary plasmacytomas. Specifically, the expression of CD166 in extramedullary plasmacytoma cells was almost 4 times lower than that in bone plasmacytoma cells, which may indicate the involvement of CD166 in the mechanisms of bone destruction. The proliferative activity of extramedullary plasmacytoma cells was shown to be higher than that of bone plasmacytoma cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-06870-w","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T14:03:32Z","timestamp":1587564212000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry"],"prefix":"10.1186","volume":"20","author":[{"given":"Maiia V.","family":"Firsova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa P.","family":"Mendeleeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla M.","family":"Kovrigina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim V.","family":"Solovev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery G.","family":"Savchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"issue":"6","key":"6870_CR1","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3109\/10428194.2012.740562","volume":"54","author":"M Weinstock","year":"2013","unstructured":"Weinstock M, Ghobrial IM. Extramedullary multiple myeloma. Leuk Lymphoma. 2013;54(6):1135\u201341. https:\/\/doi.org\/10.3109\/10428194.2012.740562.","journal-title":"Leuk Lymphoma."},{"issue":"8","key":"6870_CR2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","volume":"127","author":"C Touzeau","year":"2016","unstructured":"Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood. 2016;127(8):971\u20136. https:\/\/doi.org\/10.1182\/blood-2015-07-635383.","journal-title":"Blood."},{"issue":"28","key":"6870_CR3","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","volume":"29","author":"J Blad\u00e9","year":"2011","unstructured":"Blad\u00e9 J, Fern\u00e1ndez de Larrea C, Rosi\u00f1ol L, Cibeira MT, Jim\u00e9nez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805\u201312. https:\/\/doi.org\/10.1200\/JCO.2011.34.9290.","journal-title":"J Clin Oncol"},{"issue":"10","key":"6870_CR4","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TLY, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068\u201376. https:\/\/doi.org\/10.1182\/blood-2009-03-213280.","journal-title":"Blood."},{"issue":"2","key":"6870_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdp329","volume":"21","author":"M Varettoni","year":"2010","unstructured":"Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol Off J Eur Soc Med Oncol. 2010;21(2):325\u201330. https:\/\/doi.org\/10.1093\/annonc\/mdp329.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"6","key":"6870_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/bjh.13382","volume":"169","author":"C Varga","year":"2015","unstructured":"Varga C, Xie W, Laubach J, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015;169(6):843\u201350. https:\/\/doi.org\/10.1111\/bjh.13382.","journal-title":"Br J Haematol"},{"issue":"2","key":"6870_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1080\/10428190802657751","volume":"50","author":"P Wu","year":"2009","unstructured":"Wu P, Davies FE, Boyd K, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma. 2009;50(2):230\u20135. https:\/\/doi.org\/10.1080\/10428190802657751.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"6870_CR8","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","volume":"97","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97(11):1761\u20137. https:\/\/doi.org\/10.3324\/haematol.2012.065698.","journal-title":"Haematologica."},{"issue":"1","key":"6870_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1600-0609.2008.01087.x","volume":"81","author":"J Cerny","year":"2008","unstructured":"Cerny J, Fadare O, Hutchinson L, Wang SA. Clinicopathological features of extramedullary recurrence\/relapse of multiple myeloma. Eur J Haematol. 2008;81(1):65\u20139. https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01087.x.","journal-title":"Eur J Haematol"},{"issue":"1","key":"6870_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3324\/haematol.10297","volume":"92","author":"MA Dawson","year":"2007","unstructured":"Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica. 2007;92(1):143\u20134 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17229655. Accessed June 2, 2017.","journal-title":"Haematologica."},{"issue":"8","key":"6870_CR11","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.leukres.2009.01.036","volume":"33","author":"E Katodritou","year":"2009","unstructured":"Katodritou E, Gastari V, Verrou E, et al. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? Leuk Res. 2009;33(8):1137\u201340. https:\/\/doi.org\/10.1016\/j.leukres.2009.01.036.","journal-title":"Leuk Res"},{"issue":"1","key":"6870_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/1097-0142(196901)23:1<167::AID-CNCR2820230122>3.0.CO;2-0","volume":"23","author":"MW Pasmantier","year":"1969","unstructured":"Pasmantier MW, Azar HA. Extraskeletal spread in multiple plasma cell myeloma. A review of 57 autopsied cases. Cancer. 1969;23(1):167\u201374 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/5763250. Accessed May 18, 2017.","journal-title":"Cancer."},{"issue":"4","key":"6870_CR13","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3892\/or.2013.2254","volume":"29","author":"AA Al Zobair","year":"2013","unstructured":"Al Zobair AA, Al Obeidy BF, Yang L, et al. Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancer. Oncol Rep. 2013;29(4):1524\u201332. https:\/\/doi.org\/10.3892\/or.2013.2254.","journal-title":"Oncol Rep"},{"issue":"2","key":"6870_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ejcts.2011.05.009","volume":"41","author":"R Franco","year":"2012","unstructured":"Franco R, Pirozzi G, Scala S, et al. CXCL12-binding receptors expression in non-small cell lung cancer relates to tumoral microvascular density and CXCR4 positive circulating tumoral cells in lung draining venous blood. Eur J Cardiothorac Surg. 2012;41(2):368\u201375. https:\/\/doi.org\/10.1016\/j.ejcts.2011.05.009.","journal-title":"Eur J Cardiothorac Surg"},{"key":"6870_CR15","doi-asserted-by":"publisher","unstructured":"Johnson NA, Slack GW, Savage KJ, Johnson NA et al. 1. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone \/ N. A. Johnson, G. W. Slack, K. J. Savage, J. M. Connors, S. ben-Neriah, S. Rogi. J Clin Oncol 2012;30(28):3452\u20133459. doi:https:\/\/doi.org\/10.1200\/JCO.2011.41.0985.","DOI":"10.1200\/JCO.2011.41.0985"},{"issue":"10","key":"6870_CR16","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.leukres.2009.01.010","volume":"33","author":"N Sheth","year":"2009","unstructured":"Sheth N, Yeung J, Chang H. p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. Leuk Res. 2009;33(10):1357\u201360. https:\/\/doi.org\/10.1016\/j.leukres.2009.01.010.","journal-title":"Leuk Res"},{"issue":"4","key":"6870_CR17","first-page":"768","volume":"4","author":"S Shafaei","year":"2013","unstructured":"Shafaei S, Sharbatdaran M, Kamrani G, Khafri S. The association between CD166 detection rate and clinicopathologic parameters of patients with colorectal cancer. Casp J Intern Med. 2013;4(4):768\u201372 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24294471 Accessed June 2, 2017.","journal-title":"Casp J Intern Med"},{"issue":"4","key":"6870_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10585-007-9108-4","volume":"25","author":"I Vande Broek","year":"2008","unstructured":"Vande Broek I, Vanderkerken K, Van Camp B, Van Riet I. Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis. 2008;25(4):325\u201334. https:\/\/doi.org\/10.1007\/s10585-007-9108-4.","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"6870_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1046\/j.1365-2141.2002.03258.x","volume":"116","author":"IMS Dahl","year":"2002","unstructured":"Dahl IMS, Rasmussen T, Kauric G, Husebekk A. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol. 2002;116(2):273\u20137 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11841427. .","journal-title":"Br J Haematol"},{"issue":"23","key":"6870_CR20","doi-asserted-by":"publisher","first-page":"6901","DOI":"10.1158\/0008-5472.CAN-16-0517","volume":"76","author":"L Xu","year":"2016","unstructured":"Xu L, Mohammad KS, Wu H, et al. Cell adhesion molecule CD166 drives malignant progression and Osteolytic disease in multiple myeloma. Cancer Res. 2016;76(23):6901\u201310. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0517.","journal-title":"Cancer Res"},{"issue":"7","key":"6870_CR21","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","volume":"109","author":"Y Alsayed","year":"2007","unstructured":"Alsayed Y, Ngo H, Runnels J, et al. Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007;109(7):2708\u201317. https:\/\/doi.org\/10.1182\/blood-2006-07-035857.","journal-title":"Blood."},{"issue":"7","key":"6870_CR22","first-page":"539","volume":"1","author":"T Hideshima","year":"2002","unstructured":"Hideshima T, Chauhan D, Hayashi T, et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther. 2002;1(7):539\u201344 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12479272. .","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"6870_CR23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/bjh.13383","volume":"169","author":"M Weinstock","year":"2015","unstructured":"Weinstock M, Aljawai Y, Morgan EA, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015;169(6):851\u20138. https:\/\/doi.org\/10.1111\/bjh.13383.","journal-title":"Br J Haematol"},{"issue":"8","key":"6870_CR24","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1182\/blood.V97.8.2522","volume":"97","author":"DP Steensma","year":"2001","unstructured":"Steensma DP, Gertz MA, Greipp PR, et al. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood. 2001;97(8):2522\u20133 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11290618 Accessed Aug 30, 2017.","journal-title":"Blood."},{"issue":"7","key":"6870_CR25","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00277-012-1414-5","volume":"91","author":"L Rasche","year":"2012","unstructured":"Rasche L, Bernard C, Topp MS, et al. Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. Ann Hematol. 2012;91(7):1031\u20137. https:\/\/doi.org\/10.1007\/s00277-012-1414-5.","journal-title":"Ann Hematol"},{"issue":"1","key":"6870_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/bjh.12223","volume":"161","author":"L Billecke","year":"2013","unstructured":"Billecke L, Murga Penas EM, May AM, et al. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol. 2013;161(1):87\u201394. https:\/\/doi.org\/10.1111\/bjh.12223.","journal-title":"Br J Haematol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06870-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-06870-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06870-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T19:32:09Z","timestamp":1619033529000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-06870-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,22]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6870"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-06870-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.15623\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.15623\/v2","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,22]]},"assertion":[{"value":"19 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was given by each person, according to the guidelines of local ethical committees and the Helsinki Declaration. This study was approved by the Local Ethical Committee of <u>FSFI \u00abNational Research Center for Hematology\u00bb of the Ministry of Healthcare of the Russian Federation.<\/u>","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no conflicts of interest in this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"346"}}